| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
20,694 |
15,312 |
$4.45M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
27,337 |
23,217 |
$3.51M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
10,909 |
7,169 |
$2.56M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,544 |
4,483 |
$1.49M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
11,884 |
9,253 |
$952K |
| 80053 |
Comprehensive metabolic panel |
27,324 |
22,058 |
$906K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
14,983 |
4,644 |
$853K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
19,160 |
10,470 |
$766K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,529 |
2,208 |
$761K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,804 |
7,001 |
$560K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,343 |
1,103 |
$511K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
12,125 |
3,106 |
$506K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,392 |
2,785 |
$495K |
| 36415 |
Collection of venous blood by venipuncture |
73,211 |
34,179 |
$494K |
| 71046 |
Radiologic examination, chest; 2 views |
8,127 |
6,719 |
$482K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,988 |
3,532 |
$460K |
| 71045 |
Radiologic examination, chest; single view |
9,839 |
7,596 |
$439K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
25,964 |
21,328 |
$425K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
13,489 |
5,240 |
$388K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
9,215 |
5,182 |
$307K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
795 |
323 |
$301K |
| 96376 |
|
3,449 |
2,308 |
$268K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,253 |
3,717 |
$261K |
| 74018 |
|
4,544 |
3,444 |
$238K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
10,561 |
8,020 |
$236K |
| 83690 |
|
9,116 |
7,572 |
$218K |
| 84484 |
|
7,837 |
6,304 |
$208K |
| 73564 |
|
2,106 |
1,649 |
$195K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
1,113 |
1,007 |
$187K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,380 |
2,283 |
$185K |
| 81001 |
|
15,525 |
12,995 |
$174K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,302 |
3,589 |
$174K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,217 |
4,594 |
$170K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
5,173 |
4,019 |
$161K |
| 73630 |
|
2,368 |
2,043 |
$158K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,240 |
697 |
$157K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,892 |
4,495 |
$154K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,954 |
2,211 |
$149K |
| 73610 |
|
1,978 |
1,637 |
$143K |
| 73030 |
|
2,012 |
1,529 |
$139K |
| 72100 |
|
1,893 |
1,567 |
$138K |
| 73130 |
|
1,763 |
1,494 |
$134K |
| 83880 |
|
1,644 |
1,429 |
$120K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
4,532 |
3,057 |
$119K |
| 81025 |
|
6,526 |
5,702 |
$113K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,840 |
1,585 |
$112K |
| 87040 |
|
2,430 |
1,812 |
$110K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,848 |
1,636 |
$108K |
| 80061 |
Lipid panel |
4,044 |
3,613 |
$103K |
| 83520 |
|
1,787 |
1,447 |
$102K |
| 83735 |
|
4,701 |
3,651 |
$101K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,757 |
5,319 |
$101K |
| 52356 |
|
105 |
80 |
$96K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
4,414 |
3,410 |
$96K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
2,426 |
776 |
$91K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
382 |
323 |
$89K |
| 85027 |
|
6,885 |
5,431 |
$88K |
| 83605 |
|
3,619 |
2,873 |
$86K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
185 |
167 |
$79K |
| J1212 |
Injection, dmso, dimethyl sulfoxide, 50%, 50 ml |
204 |
156 |
$78K |
| 73110 |
|
1,105 |
897 |
$75K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
4,370 |
1,188 |
$66K |
| 71271 |
|
433 |
393 |
$66K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,041 |
610 |
$66K |
| 87186 |
|
2,348 |
1,971 |
$63K |
| 84145 |
|
686 |
589 |
$60K |
| 71250 |
|
466 |
384 |
$59K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,170 |
2,241 |
$59K |
| 87081 |
|
3,005 |
2,225 |
$58K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,560 |
1,224 |
$57K |
| 85610 |
|
3,903 |
3,006 |
$55K |
| 97162 |
|
803 |
746 |
$52K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,113 |
779 |
$51K |
| 84439 |
|
2,673 |
2,416 |
$48K |
| G0378 |
Hospital observation service, per hour |
292 |
178 |
$47K |
| 85379 |
|
1,853 |
1,675 |
$46K |
| 76536 |
|
252 |
223 |
$42K |
| 76000 |
|
816 |
628 |
$41K |
| 93017 |
|
389 |
345 |
$41K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,809 |
2,833 |
$41K |
| 93971 |
|
182 |
161 |
$39K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,269 |
2,008 |
$39K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
249 |
221 |
$38K |
| G0410 |
Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes |
532 |
77 |
$38K |
| 29125 |
|
428 |
388 |
$37K |
| 86140 |
|
2,494 |
2,198 |
$35K |
| 73502 |
|
528 |
401 |
$35K |
| 72040 |
|
434 |
347 |
$32K |
| 12001 |
|
200 |
173 |
$32K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
233 |
208 |
$32K |
| 82150 |
|
1,617 |
1,354 |
$31K |
| 80074 |
|
366 |
325 |
$31K |
| C1769 |
Guide wire |
678 |
478 |
$28K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
7,766 |
6,472 |
$26K |
| 84481 |
|
973 |
911 |
$24K |
| 82962 |
|
2,115 |
1,420 |
$23K |
| 81003 |
|
4,959 |
4,026 |
$23K |
| 82607 |
|
986 |
887 |
$23K |
| 87522 |
Neg quan hep c or qual rna |
210 |
183 |
$23K |
| 85730 |
|
845 |
748 |
$22K |
| 82570 |
|
1,400 |
1,166 |
$21K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
264 |
207 |
$21K |
| 72131 |
|
125 |
107 |
$20K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
72 |
65 |
$19K |
| 52332 |
|
26 |
24 |
$19K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,008 |
3,156 |
$19K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
10,176 |
7,417 |
$18K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
338 |
310 |
$18K |
| 85652 |
|
550 |
512 |
$17K |
| 85651 |
|
1,526 |
1,350 |
$17K |
| 52260 |
|
47 |
39 |
$17K |
| 90715 |
|
594 |
548 |
$17K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
104 |
82 |
$15K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
239 |
74 |
$15K |
| 97535 |
Self-care/home management training, each 15 minutes |
292 |
149 |
$15K |
| 0240U |
|
647 |
458 |
$15K |
| 87420 |
|
517 |
471 |
$15K |
| 80050 |
General health panel |
346 |
316 |
$14K |
| 86701 |
|
259 |
239 |
$14K |
| 96367 |
|
168 |
128 |
$13K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
674 |
613 |
$13K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
4,057 |
2,158 |
$13K |
| 52224 |
|
14 |
14 |
$13K |
| 82805 |
|
324 |
235 |
$12K |
| J2704 |
Injection, propofol, 10 mg |
3,199 |
2,427 |
$12K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
369 |
345 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
604 |
567 |
$11K |
| 95806 |
|
53 |
51 |
$11K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,493 |
3,019 |
$11K |
| 87070 |
|
519 |
398 |
$11K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
76 |
46 |
$10K |
| 82043 |
|
378 |
330 |
$10K |
| 87077 |
|
467 |
386 |
$10K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,876 |
1,773 |
$10K |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
138 |
81 |
$10K |
| 73080 |
|
220 |
157 |
$9K |
| Q3014 |
Telehealth originating site facility fee |
648 |
561 |
$9K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
46 |
41 |
$8K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,376 |
1,081 |
$8K |
| 97161 |
|
116 |
105 |
$8K |
| 83540 |
|
467 |
431 |
$8K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
61 |
56 |
$8K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
14 |
12 |
$8K |
| 29515 |
|
105 |
102 |
$8K |
| 71101 |
|
100 |
76 |
$8K |
| 10060 |
|
81 |
71 |
$8K |
| 52214 |
|
12 |
12 |
$7K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
47 |
45 |
$6K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
553 |
462 |
$6K |
| 74022 |
|
65 |
63 |
$6K |
| 73090 |
|
86 |
76 |
$6K |
| 82550 |
|
300 |
246 |
$6K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
244 |
213 |
$6K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
2,917 |
2,002 |
$6K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,124 |
1,481 |
$6K |
| J3490 |
Unclassified drugs |
438 |
138 |
$6K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
84 |
81 |
$5K |
| 78227 |
|
27 |
15 |
$5K |
| 76830 |
Ultrasound, transvaginal |
25 |
25 |
$5K |
| 83550 |
|
267 |
252 |
$5K |
| 82140 |
|
135 |
105 |
$5K |
| 82728 |
|
150 |
138 |
$5K |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
1,406 |
1,015 |
$4K |
| 80076 |
|
215 |
195 |
$4K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
15 |
12 |
$4K |
| J2785 |
Injection, regadenoson, 0.1 mg |
29 |
25 |
$4K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,520 |
1,016 |
$4K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
48 |
12 |
$4K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
289 |
182 |
$4K |
| C9113 |
Injection, pantoprazole sodium, per vial |
934 |
747 |
$3K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
376 |
262 |
$3K |
| 87486 |
|
137 |
98 |
$3K |
| 72072 |
|
45 |
41 |
$3K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
184 |
153 |
$3K |
| 94760 |
|
274 |
182 |
$3K |
| 84702 |
|
71 |
63 |
$3K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
29 |
25 |
$3K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,207 |
1,028 |
$2K |
| 86038 |
|
90 |
83 |
$2K |
| 93000 |
|
92 |
84 |
$2K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,144 |
829 |
$2K |
| J2060 |
Injection, lorazepam, 2 mg |
759 |
496 |
$2K |
| 87581 |
|
83 |
80 |
$2K |
| 36416 |
|
247 |
179 |
$2K |
| 36600 |
|
96 |
73 |
$2K |
| 82948 |
|
355 |
209 |
$2K |
| 82947 |
|
542 |
404 |
$2K |
| 72110 |
|
24 |
24 |
$2K |
| 73562 |
|
32 |
27 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
83 |
80 |
$2K |
| 73590 |
|
32 |
25 |
$2K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
636 |
516 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
36 |
28 |
$2K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
625 |
550 |
$2K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
14 |
12 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
36 |
28 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
43 |
36 |
$1K |
| 97116 |
|
31 |
13 |
$1K |
| 83516 |
|
26 |
24 |
$1K |
| 82803 |
|
13 |
12 |
$1K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
111 |
96 |
$1K |
| 84153 |
|
25 |
25 |
$983.10 |
| J2720 |
Injection, protamine sulfate, per 10 mg |
49 |
40 |
$972.19 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
26 |
25 |
$859.16 |
| 97163 |
|
12 |
12 |
$815.51 |
| 86200 |
|
27 |
25 |
$808.46 |
| 29505 |
|
14 |
14 |
$764.13 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13 |
13 |
$758.65 |
| 86431 |
|
56 |
54 |
$754.11 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
68 |
61 |
$711.04 |
| 84550 |
|
53 |
37 |
$673.79 |
| 80320 |
|
14 |
13 |
$635.07 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
358 |
293 |
$581.74 |
| 82553 |
|
22 |
14 |
$536.19 |
| 82746 |
|
30 |
25 |
$535.63 |
| 80143 |
|
13 |
12 |
$519.51 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
98 |
87 |
$461.29 |
| 51702 |
|
13 |
12 |
$429.84 |
| 84100 |
|
18 |
16 |
$388.19 |
| 81015 |
|
375 |
306 |
$383.85 |
| 82507 |
|
17 |
12 |
$285.64 |
| 82131 |
|
17 |
12 |
$275.64 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12 |
12 |
$271.01 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
33 |
32 |
$264.10 |
| A9537 |
Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries |
18 |
14 |
$262.46 |
| 83945 |
|
17 |
12 |
$253.65 |
| J7050 |
Infusion, normal saline solution, 250 cc |
87 |
70 |
$240.16 |
| 82248 |
|
14 |
12 |
$238.69 |
| 83935 |
|
17 |
12 |
$233.70 |
| 86430 |
|
14 |
12 |
$195.85 |
| C1758 |
Catheter, ureteral |
38 |
28 |
$178.40 |
| 82340 |
|
30 |
24 |
$168.52 |
| 82009 |
|
14 |
13 |
$153.96 |
| J1630 |
Injection, haloperidol, up to 5 mg |
45 |
42 |
$153.04 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
27 |
25 |
$151.84 |
| 84133 |
|
17 |
12 |
$149.82 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
31 |
13 |
$147.22 |
| 84300 |
|
17 |
12 |
$143.82 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
229 |
202 |
$138.39 |
| 80069 |
|
23 |
15 |
$129.24 |
| 82436 |
|
17 |
12 |
$127.82 |
| 84560 |
|
17 |
12 |
$121.82 |
| 94664 |
|
93 |
82 |
$110.69 |
| 84105 |
|
17 |
12 |
$103.83 |
| 84392 |
|
17 |
12 |
$83.88 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
16 |
13 |
$72.80 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
16 |
13 |
$35.06 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
46 |
43 |
$35.04 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
12 |
12 |
$3.05 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
332 |
289 |
$0.63 |
| A9270 |
Non-covered item or service |
45 |
24 |
$0.00 |